<DOC>
	<DOCNO>NCT01651000</DOCNO>
	<brief_summary>This study evaluate efficacy CTAP101 Capsules versus placebo reduce intact parathyroid hormone ( iPTH ) least 30 % pretreatment baseline ; safety tolerability CTAP101 also evaluate</brief_summary>
	<brief_title>Safety Efficacy CTAP101 Treat Secondary Hyperparathyroidism Stage 3 4 CKD Vitamin D Insufficiency</brief_title>
	<detailed_description>This phase 3 , multi-center , randomize , double-blind , placebo-controlled study evaluate efficacy safety CTAP101 Capsules administer 26 week treat SHPT subject ≥18 year age stage 3 4 CKD vitamin D insufficiency . The study conduct approximately 40 site within United States ( US ) . Approximately 550 subject screen randomize approximately 210 eligible subject , stratify CKD stage ( approximately 105 subject stage ) 2:1 ratio receive either CTAP101 Capsules match placebo . An Interactive Voice Response System ( IVRS ) provide study treatment group assignment use computer-generated randomization code provide IVRS vendor . Subjects receive initial daily dose 1 capsule ( CTAP101 Capsules , 30 µg , match placebo ) first 12 week . After l2 week ( visit 8 ) per pre-defined criterion , dose may increase blinded fashion IVRS oversight independent medical monitor .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>1 . Urinary albumin excretion ≤ 3000 mcg/mg creatinine 2 . Stage 3 4 CKD 3 . Plasma iPTH : ≥ 85 pg/mL &lt; 500 pg/mL 4 . Serum Ca : ≥ 8.4 mg/dL &lt; 9.8 mg/dL 5 . Serum P : ≥ 2.0 mg/dL &lt; 5.0 mg/dL 6 . Serum 25hydroxyvitamin D : ≥ 10 ng/mL &lt; 30 ng/mL . 7 . Stable dose Vitamin D therapy ≤ 1600 IU/day receive dose least 2 month 1 . History kidney transplant parathyroidectomy 2 . Spot urine calcium : creatinine ratio &gt; 0.2 ( &gt; 200 mg/g Cr ) 3 . Current serious illness , malignancy , HIV , liver disease , cardiovascular event hepatitis 4 . Currently dialysis 5 . Use pharmacological dose ergocalciferol cholecalciferol ( ≥ 50,000 IU mcg per month ) study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Parathyroid Diseases</keyword>
	<keyword>Renal Insufficiency</keyword>
	<keyword>Kidney Failure , Chronic</keyword>
	<keyword>Hyperparathyroidism , Secondary</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Hyperparathyroidism</keyword>
	<keyword>Kidney Diseases</keyword>
	<keyword>Kidney Failure</keyword>
	<keyword>Renal Insufficiency , Chronic</keyword>
</DOC>